Education
About Us
Working with TipRanks
Follow Us
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
PHIO Stock Chart & Stats
$2.06
-$0.09(-4.97%)
At close: 4:00 PM EST
$2.06
-$0.09(-4.97%)
Day’s Range― - ―
52-Week Range$0.97 - $9.79
Previous CloseN/A
Volume62.29K
Average Volume (3M)137.46K
Market Cap
$11.83M
Enterprise Value$492.91K
Total Cash (Recent Filing)$10.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Nov 06, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding5,726,750
10 Day Avg. Volume82,534
30 Day Avg. Volume137,459
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue7.04
Enterprise Value/Gross Profit-0.81
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$14.00Price Target Upside579.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe PH-762 Phase 1b study continued to advance in the clinic, showing impressive efficacy in each cohort.
Market PotentialDespite the crowded skin cancer therapy market, there is a high unmet need due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.
Safety ProfilePH-762 remains safe and well tolerated, with no dose-limiting toxicities, serious adverse events, or clinically meaningful treatment-emergent adverse reactions reported.
Bears Say
Phio Pharmaceuticals News
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $0.96 and its highest was $9.79 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $11.83M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 6 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Phio Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.09.
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -0.45.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 5,726,750 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Phio Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -0.457%.
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company specializes in the field of RNA interference (RNAi) and is pioneering the development of self-delivering RNAi (sd-rxRNA) therapeutics aimed at enhancing the efficacy of existing cancer treatments by targeting various pathways involved in tumor growth and immune evasion.
PHIO Stock 12 Month Forecast
Average Price Target
$14.00
▲(579.61% Upside)
Technical Analysis
Ibio
―
Evogene
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Ownership Overview
7.56% Insiders
2.32% Mutual Funds
0.25% Other Institutional Investors
89.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---